COST- EFFECTIVENESS OF PNEUMOCOCCAL VACCINATION FOR ADULTS AGED 60 YEARS AND OLDER IN PERU

被引：0
|
作者：
Figueroa, J. [1 ]
Owusu-Edusei, K. [2 ]
Valenzuela, G. [1 ]
Cossrow, N. [3 ]
Johnson, K. D. [3 ]
Parellada, C. [4 ]
机构：
[1] MSD Peru, Market Access, Lima, Peru
[2] Merck & Co Inc, Biostat Res Decis Sci BARDS, Rahway, NJ USA
[3] Merck & Co Inc, Ctr Observat & Real World Evidence, Rahway, NJ USA
[4] MSD Brazil, Ctr Observat & Realworld Evidence CORE Latin Amer, Sao Paulo, SP, Brazil
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE745
引用
收藏
页码：S198 / S198
页数：1
相关论文
共 50 条
  • [31] Cost-Effectiveness of Newly Recommended Pneumococcal Vaccination Strategies in Older Underserved Minority Adults in the USA
    Kenneth J. Smith
    Angela R. Wateska
    Mary Patricia Nowalk
    Chyongchiou J. Lin
    Lee H. Harrison
    William Schaffner
    Richard K. Zimmerman
    Infectious Diseases and Therapy, 2022, 11 : 1683 - 1693
  • [32] Commentary on: Cost-effectiveness of pneumococcal vaccination and of programs to increase its uptake in US older adults
    Andrew, Melissa K.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2024, 72 (08) : 2299 - 2302
  • [33] Changes in the cost-effectiveness of pneumococcal vaccination and of programs to increase its uptake in US older adults
    Wateska, Angela R.
    Nowalk, Mary Patricia
    Altawalbeh, Shoroq M.
    Lin, Chyongchiou J.
    Harrison, Lee H.
    Schaffner, William
    Zimmerman, Richard K.
    Smith, Kenneth J.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2024, 72 (08) : 2423 - 2433
  • [34] Cost-Effectiveness of Newly Recommended Pneumococcal Vaccination Strategies in Older Underserved Minority Adults in the USA
    Smith, Kenneth J.
    Wateska, Angela R.
    Nowalk, Mary Patricia
    Lin, Chyongchiou J.
    Harrison, Lee H.
    Schaffner, William
    Zimmerman, Richard K.
    INFECTIOUS DISEASES AND THERAPY, 2022, 11 (04) : 1683 - 1693
  • [35] Cost-effectiveness of 15-valent or 20-valent pneumococcal conjugate vaccine for US adults aged 65 years and older and adults 19 years and older with underlying conditions
    Rosenthal, Melissa
    Stoecker, Charles
    Leidner, Andrew J.
    Cho, Bo-Hyun
    Pilishvili, Tamara
    Kobayashi, Miwako
    VACCINE, 2025, 44
  • [36] Cost of pneumococcal infections and cost-effectiveness analysis of pneumococcal vaccination in at risk adults and elderly in Turkey
    Akin, Levent
    Kaya, Mehmet
    Altinel, Serdar
    Durand, Laure
    HUMAN VACCINES, 2011, 7 (04): : 441 - 450
  • [37] Cost-effectiveness of PCV13 vaccination in Belgian adults aged 65-84 years at elevated risk of pneumococcal infection
    Marbaix, Sophie
    Peetermans, Willy E.
    Verhaegen, Jan
    Annemans, Lieven
    Sato, Reiko
    Mignon, Annick
    Atwood, Mark
    Weycker, Derek
    PLOS ONE, 2018, 13 (07):
  • [38] The driving habits of adults aged 60 years and older
    Gallo, JJ
    Rebok, GW
    Lesikar, SE
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 1999, 47 (03) : 335 - 341
  • [39] Laryngotracheal Reconstruction in Adults Aged 60 Years and Older
    Rehman, Saad C.
    Xie, Deborah X.
    Bekeny, James R.
    Gelbard, Alexander
    Wootten, Christopher T.
    OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2019, 160 (06) : 1065 - 1070
  • [40] Cost-Effectiveness Analysis of 23-Valent Pneumococcal Polysaccharide Vaccine Program for the Elderly Aged 60 Years or Older in Shanghai, China
    Sun, Xiaodong
    Tang, Yuekun
    Ma, Xiaoying
    Guo, Xiang
    Huang, Zhuoying
    Ren, Jia
    Qiu, Jing
    Jiang, Hongli
    Lu, Yihan
    FRONTIERS IN PUBLIC HEALTH, 2021, 9
12345